^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HK013

    i
    Other names: HK013, HK-013, HK013-G1
    Company:
    HankeMab
    Drug class:
    CD137 agonist, Mesothelin inhibitor
    Related drugs:
    1year
    A novel MSLN×4–1BB bispecific antibody for solid tumor (SITC 2023)
    Moreover, HK013-G1 is well tolerated in cynomolgus monkeys. These results show that this bsAb has the potential to develop into a new clinical therapy for cancer types with high-level MSLN expression.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MSLN (Mesothelin) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    MSLN expression
    |
    HK013
    2years
    A Novel anti-MSLN x 4-1BB bispecific antibody with Fc effect function augments the antitumor efficacy (SITC 2022)
    Compared with anti-4-1BB parent antibody and urelumab, HK013 induced weaker FcγR-mediated 4-1BB activation. Conclusions IgG1-based HK013-1 prevents tumor development by directly killing tumor cells and depleting Treg to relieve immunosuppression. Preclinical studies have shown that IgG1-based HK013-1 has good antitumor activity and safety, which may further develop its clinical potential.
    Clinical
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    HK013 • urelumab (BMS-663513)